Point-of-care diagnosis and monitoring of fibrinolysis resistance in the critically ill: results from a feasibility study

Critical Care

Research

Robert L. Medcalf¹  Jonathan G. Schoenecker²  Philip J. Crispin³  Tony Ghent⁴  Jennene J. Miller⁵  Lucy A. Coupland⁶  Anders E. Aneman⁶  David J. Rabbolini⁷ 

[1]Australian Centre for Blood Diseases, Monash University, Melbourne, Australia

[2]Department of Orthopaedics and Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA

[3]Haematology Department, The Canberra Hospital, Canberra, Australia

[4]The Australian National University Medical School, Canberra, Australia

[5]Intensive Care Unit, Gold Coast University Hospital, South Port, Australia

[6]Intensive Care Unit, Liverpool Hospital, Liverpool, Australia

[7]Intensive Care Unit, Liverpool Hospital, Liverpool, Australia

[8]Ingham Institute for Applied Medical Research, 1 Campbell St, 2170, Liverpool, NSW, Australia

[9]Kolling Institute of Medical Research, Faculty of Medicine and Health, University of Sydney, Sydney, Australia

[10]Oxford Haemophilia and Thrombosis Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

关键词: Fibrinolysis resistance;    Fibrinolytic shutdown;    Fibrinolysis;    Viscoelastic testing;    Point-of-care testing;    Tissue plasminogen activator;    Plasminogen;    Alteplase;    Personalised medicine;   

DOI  :  10.1186/s13054-023-04329-5

 received in 2022-10-31, accepted in 2023-01-22,  发布年份 2023

来源: Springer

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 6

Fig. 1

Fig. 3

13690_2023_1037_Article_IEq1.gif

Fig. 2

13690_2023_1029_Article_IEq15.gif